Role of 18F‐<scp>FDG</scp>‐<scp>PET</scp>/<scp>CT</scp> in the management of Burkitt lymphoma

Carrillo‐Cruz, Estrella; Marín-Oyaga, V.; Rodríguez, María Solé; Borrego-Dorado, I.; Vicente, Fátima de la Cruz; Cantero, Eduardo Quiroga; Pérez, Marina Manzanares; Capote, Francisco; Sánchez, Marı́a J.; Espigado, Ildefonso; Pérez-Vega, Herminia; Vázquez-Albertino, R.; Pérez‐Simón, José A.

doi:10.1111/ejh.12284

Cited by 32 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All cases of Burkitt lymphoma are FDG-avid, and PET/CT staging detects more extranodal disease than conventional staging. Of interest, occult bone marrow involvement is found and occasional clinically important upstagings occur [33].…”

Section: Pet/ct Staging In Staging Of Aggressive Non-hodgkin Lymphomasmentioning

confidence: 99%

Imaging of Non-Hodgkin Lymphomas: Diagnosis and Response-Adapted Strategies

El‐Galaly

Hutchings

2015

Cancer Treatment and Research

View full text Add to dashboard Cite

Optimal lymphoma management requires accurate pretreatment staging and reliable assessment of response, both during and after therapy. Positron emission tomography with computerized tomography (PET/CT) combines functional and anatomical imaging and provides the most sensitive and accurate methods for lymphoma imaging. New guidelines for lymphoma imaging and recently revised criteria for lymphoma staging and response assessment recommend PET/CT staging, treatment monitoring, and response evaluation in all FDG-avid lymphomas, while CT remains the method of choice for non-FDG-avid histologies. Since interim PET imaging has high prognostic value in lymphoma, a number of trials investigate PET-based, response-adapted therapy for non-Hodgkin lymphomas (NHL). PET response is the main determinant of response according to the new response criteria, but PET/CT has little or no role in routine surveillance imaging, the value which is itself questionable. This review presents from a clinical point of view the evidence for the use of imaging and primarily PET/CT in NHL before, during, and after therapy. The reader is given an overview of the current PET-based interventional NHL trials and an insight into possible future developments in the field, including new PET tracers.

show abstract

Section: Pet/ct Staging In Staging Of Aggressive Non-hodgkin Lymphomasmentioning

confidence: 99%

Imaging of Non-Hodgkin Lymphomas: Diagnosis and Response-Adapted Strategies

El‐Galaly

Hutchings

2015

Cancer Treatment and Research

View full text Add to dashboard Cite

show abstract

“…More recently, Carrillo-Cruz et al analyzed the role of 18 FDG-PET at the end of treatment using Deauville criteria. In this heterogeneous study including 13 children and 19 adults and different treatment schemes, the NPV of 18 FDG-PET reached 100% ( 27 ). Our results are consistent with these data and strengthen the literature on a homogeneous population of pediatric BL, in which all residual lesions were biopsied or resected.…”

Section: Discussionmentioning

confidence: 81%

“…In the Bakhshi et al study ( 22 ), response at interim 18 FDG-PET or CI did not predict PFS or overall survival in 34 patients with non-lymphoblastic lymphomas including 28 B-cell lymphomas. In Carrillo-Cruz’s study ( 27 ), the Deauville criteria (score ≥4 as positive) did not allow to predict outcome accurately in a heterogeneous population of BL when quantitated at the end of treatment. On the contrary, in our study, the use of Deauville criteria (score ≥4 as positive) improved specificity and PPV and 18 FDG-PET was predictive of outcome ( p = 0.011) when performed in an earlier setting (after induction chemotherapy).…”

Section: Discussionmentioning

confidence: 93%

“…This latter issue might be of great interest considering the importance of early response to chemotherapy in the prognosis and management of children BL ( 7 – 9 ). The need to achieve complete response (CR) after induction chemotherapy prior to deciding on further therapies raises the problem of residual mass depicted by conventional imaging (CI) after induction chemotherapy ( 27 ). A biopsy of these residual masses is recommended by most of treatment protocols, but it is invasive and only has value if positive.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Value and Clinical Impact of 18FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy

Bailly¹,

Eugène²,

Couec³

et al. 2014

Front. Med.

View full text Add to dashboard Cite

Objective: Burkitt lymphoma (BL) is a rare and aggressive form of B-cell lymphoma that is curable using intensive chemotherapy. Obtaining a complete response (CR) at the end of induction chemotherapy is a major prognostic factor. This study retrospectively evaluates the potential impact of 18FDG-PET in the management of children with BL after induction chemotherapy, and the prognostic performance of the Deauville criteria.Methods: Nineteen children with BL treated according to the French LMB2001 protocol between 2005 and 2012 were included. 18FDG-PET and conventional imaging (CI) were performed after induction chemotherapy to confirm CR. 18FDG-PET was interpreted according to Deauville criteria with follow-up and/or histology as the gold standard.Results: 18FDG-PET was negative in 15 cases, in agreement with CI in 9/15 cases. The six discordant cases confirmed to be negative by histology, were considered as true negative for 18FDG-PET. Negative predictive value (NPV) of CI and 18FDG-PET were 73 and 93%, respectively. The 5-year progression-free survival (PFS) was significantly higher in patients with negative 18FDG-PET than those with positive 18FDG-PET (p = 0.011).Conclusion: 18FDG-PET interpreted using Deauville criteria can help confirm CR at the end of induction chemotherapy, with a prognostic impact on 5-year PFS. Its high NPV could limit the use of residual mass biopsy. Given the small size of our population, these results need to be confirmed by future prospective studies on a larger population.

show abstract

“…Therefore, novel neuroimaging methods that may improve early diagnosis of the disease, thus improving patient prognosis, are required. In recent years, a number of studies have demonstrated that information provided by 18-fluorodeoxyglucose positron-emission tomography/CT (FDG-PET/CT) may result in greater sensitivity compared with anatomic imaging modalities (18,19).…”

Section: Discussionmentioning

confidence: 99%

Oculomotor nerve palsy as a preceding symptom of adult sporadic Burkitt lymphoma: A case report and review of the literature

Liang

Ding

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Adult sporadic Burkitt lymphoma (BL) is a rare aggressive neoplasm and represents ~1-5% of all lymphomas diagnosed in adults. The disease exhibits an aggressive clinical manifestation, which frequently involves the central nervous system (CNS) in the early stages, and is usually accompanied by abnormalities in cerebrospinal fluid (CSF) examinations and/or neuroradiography. The current study describes the rare case of a 29-year-old man who presented with oculomotor nerve palsy without palpated masses, B symptoms, peripheral blood anomaly and abnormalities of the nervous system. The patient was initially misdiagnosed with abducens diplopia, but was subsequently confirmed to have BL with early CNS invasion. Epstein-Barr virus and human immunodeficiency virus infection were negative. Intensive systemic chemotherapy with hyperfractionated cyclophosphamide, vincristine, therarubicin and dexamethasone (hyper-CVAD, cyclophosphamide 600 mg/m 2 on days 2-4; vincristine 1.4 mg/m 2 on days 5 and 12, therarubicin 50 mg/m 2 on day 5 and dexamethasone 40 mg on days 2-5 and 12-15), including intrathecal chemotherapy with methotrexate (5 mg), arabinocytidine (5 mg) and dexamethasone (5 mg), was determined as an appropriate treatment. Rituximab (375 mg/m 2 on day 1) was administered alongside chemotherapy to increase treatment efficacy. The patient temporarily underwent complete remission, but subsequently relapsed as no suitable bone marrow donor was available. Adult sporadic BL with early CNS invasion, which traditional tests such as neuroradiography and CSF examination fail to identify, is uncommon. Therefore, appropriate diagnostic tests are critical for accurate diagnosis and must be performed immediately, particularly in patients that present with unusual image and laboratory manifestations.

show abstract

Role of 18F‐FDG‐PET/CT in the management of Burkitt lymphoma

Abstract: More accurate staging can be achieved using PET/CT. NPV reaches 100%, and using a ΔSUV < 66%, a high PPV is also observed.

Cited by 32 publications

References 24 publications

Imaging of Non-Hodgkin Lymphomas: Diagnosis and Response-Adapted Strategies

Imaging of Non-Hodgkin Lymphomas: Diagnosis and Response-Adapted Strategies

Prognostic Value and Clinical Impact of 18FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy

Oculomotor nerve palsy as a preceding symptom of adult sporadic Burkitt lymphoma: A case report and review of the literature

Contact Info

Product

Resources

About